1. Hurt KJ, Guile MW, Bienstock JL, Fox HE, Wallach EE. The Johns Hopkins manual of gynecology and obstetrics. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2011.
2. National Collaborating Centre for Women's and Children's Health (GB). National Institute for Health and Clinical Excellence (GB). Royal College of Obstetricians and Gynaecologists (GB). Ectopic pregnancy and miscarriage: diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. London (GB): Royal College of Obstetricians and Gynaecologists;2012.
3. Francis O. An analysis of 1150 cases of abortions from the Government R.S.R.M. Lying-in Hospital, Madras. J Obstet Gynaecol India. 1959; 10:62–70.
4. Cunningham FG. Williams obstetrics. 24th ed. New York (NY): McGraw-Hill;2014.
5. Oliver A, Overton C. Diagnosis and management of miscarriage. Practitioner. 2014; 258:25–28. 23
6. Kripke C. Expectant management vs. surgical treatment for miscarriage. Am Fam Physician. 2006; 74:1125–1126.
7. Tunçalp Ö, Gülmezoglu AM, Souza JP. Surgical procedures for evacuating incomplete miscarriage. Cochrane Database Syst Rev. 2010; CD001993.
Article
8. Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract. 1997; 44:353–360.
9. Westhoffa C, Dasmahapatra R, Schaff E. Analgesia during at-home use of misoprostol as part of a medical abortion regimen. Contraception. 2000; 62:311–314.
Article
10. Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA, et al. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol. 2007; 109:885–894.
11. Kopp Kallner H, Fiala C, Gemzell-Danielsson K. Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion. Contraception. 2012; 85:394–397.
Article
12. Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet. 2013; 121:186–189.
Article
13. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997; 90:88–92.
Article
14. Bracken H, Dabash R, Tsertsvadze G, Posohova S, Shah M, Hajri S, et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective comparative open-label trial. Contraception. 2014; 89:181–186.
Article
15. Chong E, Tsereteli T, Nguyen NN, Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception. 2012; 86:251–256.
Article
16. Tang OS, Lau WN, Ng EH, Lee SW, Ho PC. A prospective randomized study to compare the use of repeated doses of vaginal with sublingual misoprostol in the management of first trimester silent miscarriages. Hum Reprod. 2003; 18:176–181.
Article
17. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001; 64:81–85.
Article
18. Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod. 2004; 19:81–84.
Article
19. Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG. 2004; 111:1001–1005.
Article
20. Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011; CD002855.
Article
21. Cunningham FG. Williams obstetrics. 23rd ed. New York (NY): McGraw-Hill;2010.
22. Bracken H. Family Planning Association of India (FPAI)/Gynuity Health Projects Research Group for Simplifying Medical Abortion in India. Home administration of misoprostol for early medical abortion in India. Int J Gynaecol Obstet. 2010; 108:228–232.
23. Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K. Home self-administration of vaginal misoprostol for medical abortion at 50–63 days compared with gestation of below 50 days. Hum Reprod. 2010; 25:1153–1157.
Article
24. Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2010; CD000941.
Article
25. Gómez Ponce de León R, Wing D, Fiala C. Misoprostol for intrauterine fetal death. Int J Gynaecol Obstet. 2007; 99:Suppl 2. S190–S193.
Article
26. Karki DB, Sharmqa UK, Rauniyar RK. Study of accuracy of commonly used fetal parameters for estimation of gestational age. JNMA J Nepal Med Assoc. 2006; 45:233–237.
27. Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome--one century later. Fertil Steril. 2008; 89:759–779.
Article
28. Engelbrechtsen L, Langhoff-Roos J, Kjer JJ, Istre O. Placenta accreta: adherent placenta due to Asherman syndrome. Clin Case Rep. 2015; 3:175–178.
Article
29. von Hertzen H, Baird D; Bellagio Study and Conference Center. Frequently asked questions about medical abortion. Contraception. 2006; 74:3–10.
Article